Spero Therapeutics (NASDAQ:SPRO) Earns Hold Rating from TD Cowen

TD Cowen restated their hold rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report released on Monday, MarketBeat Ratings reports.

Several other equities research analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. HC Wainwright lowered their price target on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, November 4th.

Spero Therapeutics Stock Performance

SPRO stock opened at $1.19 on Monday. The firm has a market capitalization of $64.88 million, a price-to-earnings ratio of 17.00 and a beta of 0.63. The firm has a 50 day moving average price of $1.28 and a 200-day moving average price of $1.36. Spero Therapeutics has a 52-week low of $1.01 and a 52-week high of $1.89.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the period. Acadian Asset Management LLC raised its position in Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Murchinson Ltd. lifted its holdings in shares of Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the period. Virtu Financial LLC purchased a new position in shares of Spero Therapeutics during the first quarter valued at $31,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after acquiring an additional 121,492 shares in the last quarter. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.